Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2506) 2506
Book Chapter (15) 15
Newsletter (14) 14
Newspaper Article (9) 9
Magazine Article (8) 8
Publication (5) 5
Dissertation (4) 4
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2122) 2122
science & technology (1815) 1815
life sciences & biomedicine (1791) 1791
female (1348) 1348
male (1300) 1300
enoxaparin - administration & dosage (1225) 1225
enoxaparin (980) 980
enoxaparin - therapeutic use (958) 958
middle aged (947) 947
anticoagulants - administration & dosage (900) 900
aged (861) 861
anticoagulants - therapeutic use (759) 759
biological and medical sciences (703) 703
medical sciences (702) 702
adult (662) 662
enoxaparin - adverse effects (638) 638
cardiovascular system & cardiology (621) 621
anticoagulants - adverse effects (552) 552
anticoagulants (549) 549
treatment outcome (535) 535
abridged index medicus (446) 446
hematology (430) 430
peripheral vascular disease (386) 386
pharmacology. drug treatments (380) 380
risk factors (372) 372
venous thromboembolism - prevention & control (356) 356
thromboembolism (354) 354
drug therapy (337) 337
heparin (323) 323
aged, 80 and over (315) 315
cardiac & cardiovascular systems (314) 314
surgery (306) 306
pharmacology & pharmacy (297) 297
hemorrhage - chemically induced (288) 288
prospective studies (282) 282
venous thrombosis - prevention & control (268) 268
fibrinolytic agents - administration & dosage (264) 264
drug administration schedule (263) 263
general & internal medicine (263) 263
enoxaparin - pharmacology (259) 259
venous thromboembolism (257) 257
retrospective studies (254) 254
blood. blood coagulation. reticuloendothelial system (245) 245
thrombosis (237) 237
dose-response relationship, drug (235) 235
time factors (234) 234
fibrinolytic agents - therapeutic use (232) 232
postoperative complications - prevention & control (228) 228
cardiology. vascular system (222) 222
thromboembolism - prevention & control (218) 218
heparin - therapeutic use (215) 215
injections, subcutaneous (214) 214
medicine & public health (206) 206
dosage and administration (204) 204
heparin - administration & dosage (201) 201
medicine, general & internal (201) 201
analysis (188) 188
animals (183) 183
anticoagulants - pharmacology (183) 183
care and treatment (183) 183
factor xa inhibitors (178) 178
drug therapy, combination (175) 175
low-molecular-weight heparin (175) 175
heparin, low-molecular-weight - administration & dosage (171) 171
heparin, low-molecular-weight - therapeutic use (171) 171
health aspects (168) 168
double-blind method (166) 166
prevention (163) 163
administration, oral (160) 160
venous thrombosis - drug therapy (160) 160
adolescent (157) 157
follow-up studies (155) 155
venous thromboembolism - etiology (151) 151
enoxaparin - pharmacokinetics (150) 150
research (147) 147
pregnancy (143) 143
myocardial infarction - drug therapy (142) 142
coronary heart disease (139) 139
rivaroxaban (137) 137
randomized controlled trials as topic (133) 133
fibrinolytic agents - adverse effects (131) 131
low molecular weight heparin (130) 130
risk assessment (128) 128
cardiology (127) 127
pulmonary embolism (126) 126
venous thrombosis (125) 125
heart attacks (122) 122
anticoagulation (119) 119
anticoagulants - pharmacokinetics (116) 116
heparin - adverse effects (115) 115
incidence (114) 114
thrombosis - prevention & control (112) 112
clinical trials (109) 109
enoxaparin - economics (108) 108
blood and lymphatic vessels (107) 107
patients (107) 107
pulmonary embolism - prevention & control (107) 107
acute disease (106) 106
prophylaxis (106) 106
glycosaminoglycans (105) 105
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2458) 2458
German (37) 37
Spanish (33) 33
Russian (30) 30
French (21) 21
Portuguese (11) 11
Norwegian (6) 6
Chinese (4) 4
Danish (4) 4
Italian (4) 4
Ukrainian (4) 4
Czech (3) 3
Polish (3) 3
Japanese (2) 2
Korean (2) 2
Bulgarian (1) 1
Hungarian (1) 1
Persian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
by Kakkar, Ajay K, Prof and Brenner, Benjamin, Prof and Dahl, Ola E, MD and Eriksson, Bengt I, MD and Mouret, Patrick, MD and Muntz, Jim, MD and Soglian, Andrea G, MD and Pap, Ákos F and Misselwitz, Frank, MD and Haas, Sylvia, Prof and for the RECORD2 Investigators and RECORD2 Investigators and Sahlgrenska akademin and Institute of Clinical Sciences and Institutionen för kliniska vetenskaper and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty - A meta-analysis
by Sorrel E. Wolowacz and Neil S. Roskell and Jonathan M. Plumb and Joseph A. Caprini and Bengt I. Eriksson and Sahlgrenska akademin and Institute of Clinical Sciences and Institutionen för kliniska vetenskaper and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
Thrombosis and haemostasis, ISSN 0340-6245, 01/2009, Volume 101, Issue 1, pp. 77 - 85
anticoagulants | thrombosis | prophylaxis | Embolism | Meta-analysis | Anticoagulants | Thrombosis | Prophylaxis | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Hematologic and hematopoietic diseases | Biological and medical sciences | Blood coagulation. Blood cells | Molecular and cellular biology | Medical sciences | Platelet diseases and coagulopathies | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Arthroplasty, Replacement, Knee - adverse effects | Humans | Dabigatran | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Drug Administration Schedule | Risk Assessment | Administration, Oral | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Arthroplasty, Replacement, Hip - adverse effects | Venous Thromboembolism - etiology | Hemorrhage - chemically induced | Index Medicus | Administration | Phase III as Topic | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Pyridines/administration & dosage/adverse effects/therapeutic use | Arthroplasty | Replacement | Oral | Clinical Trials | Kirurgi | Knee/adverse effects | Hemorrhage/chemically induced | Venous Thromboembolism/etiology/mortality/prevention & control | Hip/adverse effects | Anticoagulants/administration & dosage/adverse effects/therapeutic use | Surgery | Enoxaparin/administration & dosage/adverse effects/therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II): A randomised, double-blind, non-inferiority trial
by Eriksson, Bengt I and Dahl, Ola E and Huo, Michael H and Kurth, Andreas A and Hantel, Stefan and Hermansson, Karin and Schnee, Janet M and Friedman, Richard J and RE-NOVATE Il Study Grp and RE-NOVATE II Study Group and for the RE-NOVATE II Study Group and Sahlgrenska akademin and Institutionen för kliniska vetenskaper, Avdelningen för ortopedi and Institute of Clinical Sciences, Department of Orthopaedics and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
Thrombosis and haemostasis, ISSN 0340-6245, 04/2011, Volume 105, Issue 4, pp. 721 - 729
Dabigatran etexilate | Oral anticoagulant | Total hip arthroplasty | Venous thromboembolism | Prophylaxis | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Cardiology. Vascular system | Hematologic and hematopoietic diseases | Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous | Biological and medical sciences | Blood coagulation. Blood cells | Molecular and cellular biology | Medical sciences | Blood and lymphatic vessels | Platelet diseases and coagulopathies | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Humans | Middle Aged | Male | Antithrombins - administration & dosage | Dabigatran | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Benzimidazoles - administration & dosage | Hemorrhage - etiology | Injections, Subcutaneous | Female | Venous Thrombosis - prevention & control | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Postoperative Complications | beta-Alanine - adverse effects | Double-Blind Method | Administration, Oral | Venous Thrombosis - mortality | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Venous Thrombosis - etiology | Venous Thromboembolism - etiology | Antithrombins - adverse effects | Survival Analysis | Arthroplasty, Replacement, Hip - mortality | Aged | Benzimidazoles | Venous Thrombosis | Oral | Hemorrhage | Antithrombins | Venous Thromboembolism | administration & dosage | Surgery | beta-Alanine | Administration | Anticoagulants | Subcutaneous | Enoxaparin | Arthroplasty | Replacement | prevention & control | Kirurgi | Hip | etiology | Injections | analogs & derivatives | adverse effects | mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Oral Apixaban for the Treatment of Acute Venous Thromboembolism
by Agnelli, Giancarlo and Buller, Harry R and Cohen, Alexander and Curto, Madelyn and Gallus, Alexander S and Johnson, Margot and Masiukiewicz, Urszula and Pak, Raphael and Thompson, John and Raskob, Gary E and Weitz, Jeffrey I and AMPLIFY Investigators
The New England journal of medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 9, pp. 799 - 808
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Follow-Up Studies | Humans | Middle Aged | Hemorrhage - mortality | Warfarin - adverse effects | Male | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - drug therapy | Warfarin - therapeutic use | Pyridones - administration & dosage | Adult | Female | Pyrazoles - adverse effects | Acute Disease | Double-Blind Method | Administration, Oral | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Pyrazoles - administration & dosage | Aged | Hemorrhage - chemically induced | Pyridones - adverse effects | Dosage and administration | Research | Thromboembolism | Drug therapy | Apixaban | Anticoagulants | Warfarin | Heart attacks | Embolisms | Thrombosis | Patients | Bleeding | Veins & arteries | Index Medicus | Abridged Index Medicus | Pyrazoles | Pyridones | Enoxaparin | Factor Xa | Hemorrhage | Life Sciences | Venous Thromboembolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty The FOXTROT Randomized Clinical Trial
by Weitz, Jeffrey I and Bauersachs, Rupert and Becker, Bastian and Berkowitz, Scott D and Freitas, Maria C. S and Lassen, Michael R and Metzig, Carola and Raskob, Gary E
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 01/2020, Volume 323, Issue 2, pp. 130 - 139
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Single-Blind Method | Pulmonary Embolism - prevention & control | Anticoagulants - administration & dosage | Humans | Middle Aged | Postoperative Complications - prevention & control | Male | Enoxaparin - adverse effects | Factor Xa Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Arthroplasty, Replacement, Knee | Female | Venous Thrombosis - prevention & control | Pyrazoles - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Anticoagulants - adverse effects | Preoperative Care | Pyrazoles - administration & dosage | Factor Xa Inhibitors - adverse effects | Aged | Hemorrhage - chemically induced | Pyridones - adverse effects | Knee | Surgical implants | Intravenous administration | Arthroplasty (knee) | Clinical trials | Risk | Criteria | Joint surgery | Joint replacement surgery | Thrombosis | Patients | Bleeding | Embolism | Body mass index | Biomedical materials | Body mass | Body size | Surgery | Monoclonal antibodies | Safety | Thromboembolism | Health risk assessment
Journal Article
Details down arrow
6. Full Text Development, in vitro and in vivo evaluation of a self-emulsifying drug delivery system (SEDDS) for oral enoxaparin administration
by Zupančič, Ožbej and Grieβinger, Julia Anita and Rohrer, Julia and Pereira de Sousa, Irene and Danninger, Lukas and Partenhauser, Alexandra and Sündermann, Nadine Elli and Laffleur, Flavia and Bernkop-Schnürch, Andreas
European journal of pharmaceutics and biopharmaceutics, ISSN 0939-6411, 12/2016, Volume 109, pp. 113 - 121
Oral LMWH delivery | Hydrophobic ion pairing | Self-emulsifying drug delivery systems (SEDDS) | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Amines - chemistry | Caco-2 Cells | Chemistry, Pharmaceutical - methods | Administration, Oral | Cell Survival | Emulsions - chemistry | Xanthenes - chemistry | Humans | Solubility | Biological Availability | Chromatography, High Pressure Liquid | Drug Carriers - chemistry | Heparin, Low-Molecular-Weight | Drug Delivery Systems | Particle Size | Enoxaparin - administration & dosage | Lipids - chemistry | Emulsifying Agents - chemistry | Enoxaparin - chemistry | Drug Liberation | Oxazines - chemistry | Diffusion | Drugs | Drug delivery systems | Analysis | Vehicles | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial
by Agnelli, G and Buller, H. R and Cohen, A and Gallus, A. S and Lee, T. C and Pak, R and Raskob, G. E and Weitz, J. I and Yamabe, T
Journal of thrombosis and haemostasis, ISSN 1538-7933, 2015, Volume 13, Issue 12, pp. 2187 - 2191
anticoagulants | cancer | enoxaparin | apixaban | venous thromboembolism | Enoxaparin | Anticoagulants | Venous thromboembolism | Apixaban | Cancer | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Recurrence | Anticoagulants - administration & dosage | Humans | Middle Aged | Warfarin - adverse effects | Male | Warfarin - administration & dosage | Enoxaparin - adverse effects | Venous Thromboembolism - drug therapy | Factor Xa Inhibitors - administration & dosage | Venous Thromboembolism - blood | Neoplasms - complications | Pyridones - administration & dosage | Enoxaparin - administration & dosage | Neoplasms - blood | Time Factors | Female | Odds Ratio | Pyrazoles - adverse effects | Venous Thromboembolism - diagnosis | Double-Blind Method | Risk Factors | Logistic Models | Treatment Outcome | Anticoagulants - adverse effects | Chi-Square Distribution | Venous Thromboembolism - etiology | Pyrazoles - administration & dosage | Factor Xa Inhibitors - adverse effects | Aged | Hemorrhage - chemically induced | Pyridones - adverse effects | Clinical trials | Warfarin | Glycosaminoglycans | Thromboembolism | Drug therapy | Analysis | Confidence intervals | Molecular weight | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Pharmacotherapy in the critically ill obese patient
by Medico, Charles J and Walsh, Patrick
Critical care clinics, ISSN 0749-0704, 2010, Volume 26, Issue 4, pp. 679 - 688
Pharmacotherapy | Dosing | Obese | Body weight | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Body Mass Index | Vancomycin - administration & dosage | Obesity - drug therapy | Carbapenems - administration & dosage | Humans | Hypnotics and Sedatives - administration & dosage | Heparin - administration & dosage | Antithrombins - administration & dosage | Cephalosporins - administration & dosage | Oxazolidinones - administration & dosage | Penicillins - administration & dosage | Recombinant Proteins - administration & dosage | Obesity - metabolism | Drug Dosage Calculations | Enoxaparin - administration & dosage | Pipecolic Acids - administration & dosage | Quinolones - administration & dosage | Aminoglycosides - administration & dosage | Protein C - administration & dosage | Fibrinolytic Agents - administration & dosage | Lipopeptides - administration & dosage | Safety
Journal Article
Details down arrow
9. Full Text The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement
by Lassen, Michael Rud and Davidson, B.L and Gallus, A and Pineo, G and Ansell, J and Deitchman, D
Journal of thrombosis and haemostasis, ISSN 1538-7933, 12/2007, Volume 5, Issue 12, pp. 2368 - 2375
Prevention | Oral anticoagulant | Total knee replacement | Surgery | Antithrombotic | Apixaban | Factor Xa inhibitor | Venous thromboembolism | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Pyrazoles - therapeutic use | Venous Thromboembolism - mortality | Arthroplasty, Replacement, Knee - adverse effects | Factor Xa Inhibitors | Humans | Middle Aged | Warfarin - adverse effects | Male | Enoxaparin - therapeutic use | North America | Warfarin - administration & dosage | Enoxaparin - adverse effects | South Australia | Venous Thromboembolism - blood | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Pyridones - administration & dosage | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Pyrazoles - adverse effects | Argentina | Drug Administration Schedule | Risk Assessment | Administration, Oral | Europe | Treatment Outcome | Factor Xa - metabolism | Venous Thromboembolism - etiology | Pyrazoles - administration & dosage | Aged | Fibrinolytic Agents - administration & dosage | Pyridones - therapeutic use | Hemorrhage - chemically induced | Israel | Pyridones - adverse effects | Anticoagulants (Medicine) | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
by Cohen, Alexander T and Spiro, Theodore E and Büller, Harry R and Haskell, Lloyd and Hu, Dayi and Hull, Russell and Mebazaa, Alexandre and Merli, Geno and Schellong, Sebastian and Spyropoulos, Alex C and Tapson, Victor and MAGELLAN Investigators
The New England journal of medicine, ISSN 0028-4793, 02/2013, Volume 368, Issue 6, pp. 513 - 523
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Public health. Hygiene-occupational medicine | Public health. Hygiene | Biological and medical sciences | General aspects | Medical sciences | Prevention and actions | Thiophenes - therapeutic use | Acute Disease | Double-Blind Method | Drug Administration Schedule | Factor Xa Inhibitors | Thiophenes - adverse effects | Administration, Oral | Humans | Middle Aged | Anticoagulants - therapeutic use | Male | Enoxaparin - therapeutic use | Anticoagulants - adverse effects | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Injections, Subcutaneous | Adult | Female | Aged | Hemorrhage - chemically induced | Venous Thromboembolism - epidemiology | Morpholines - adverse effects | Morpholines - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Dosage and administration | Product/Service Evaluations | Drug therapy | Thrombosis | Chronically ill | Blood clot | Index Medicus | Abridged Index Medicus | Anticoagulants | Enoxaparin | Factor Xa | Morpholines | Hemorrhage | Life Sciences | Venous Thromboembolism | Thiophenes | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights